We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Protherics (MM) | NASDAQ:PTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.30 | 0 | 01:00:00 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
27 October 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange
Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .
The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PROTHERICS PLC |
||||||||
Date: 27 October 2008 |
By: |
/s/ Rolf Soderstrom |
||||||
Rolf Soderstrom |
||||||||
Finance Director |
Protherics PLC
Notification of Major Interests in Shares
London, UK; Brentwood, TN, US: 27 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 27 October 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the interest notified are set out below.
The notification follows an increase in the Company's issued ordinary share capital following the conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of Protherics, as further described in the announcement made jointly by Protherics and BTG plc on 18 September 2008.
|
|
|
An acquisition or disposal of voting rights |
|
|
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|
An event changing the breakdown of voting rights |
|
|
Other (please specify): variation in issued share capital |
X |
|
2. Full name of person(s) subject to the notification obligation: |
AXA S.A., 25 Avenue Matignon, 75008 Paris and its group of companies. |
|
3. Full name of shareholder(s) (if different from 2.): |
|
|
4. Date of the transaction (and date on which the threshold is crossed or reached if different): |
26 October 2008 |
|
5. Date on which issuer notified: |
27 October 2008 |
|
6. Threshold(s) that is/are crossed or reached: |
12% |
|
|
||
7. Notified details:
|
A: Voting rights attached to shares |
|||||||
Class/type of shares if possible using the ISIN CODE |
Situation previous to the Triggering transaction |
Resulting situation after the triggering transaction |
|||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights |
|||
Direct |
Direct |
Indirect |
Direct |
Indirect |
|||
0702920
|
42,026,712 |
42,026,712 |
1,041,666 |
1,041,666 |
40,985,046 |
0.30% |
11.70 % |
B: Financial Instruments |
||||
Resulting situation after the triggering transaction |
||||
Type of financial instrument |
Expiration date |
Exercise/ Conversion Period/ Date |
Number of voting rights that may be acquired if the instrument is exercised/ converted. |
% of voting rights |
|
|
|
|
|
|
|
|
|
|
Total (A+B) |
|
Number of voting rights |
% of voting rights |
42,026,712 |
11.99% |
8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable : |
|||||
Name of Company/Fund
|
Number of Shares |
% of issued share capital |
|||
AXA Direct
|
716,666 |
|
0.20451 |
|
|
AXA Framlington Indirect
|
40,985,046 |
|
11.69573 |
|
|
AXA IM UK Direct
|
325,000 |
|
0.09274 |
|
|
Total Direct Total Indirect |
1,041,666 40,985,046 |
|
0.29726 11.69573 |
|
|
TOTAL |
42,026,712 |
|
11.99298 |
|
|
|
|||||
Proxy Voting: |
|||||
9. Name of the proxy holder: |
|
||||
10. Number of voting rights proxy holder will cease to hold: |
|
||||
11. Date on which proxy holder will cease to hold voting rights: |
|
12. Additional information: |
|
| Ends |
For further information please contact:
Protherics |
|
Nick Staples, Director of Corporate Affairs |
+44 (0) 7919 480510 |
Julie Vickers, Company Secretary |
+44 (0)1928 518010 |
|
|
Financial Dynamics - press enquiries |
|
London: Ben Atwell, Lara Mott |
+44 (0) 20 7831 3113 |
New York: John Capodanno |
+1 212 850 5600 |
Or visit www.protherics.com
1 Year Protherics Chart |
1 Month Protherics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions